May 07, 2024
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
Apr 30, 2024
Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024
Apr 25, 2024
Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study
Apr 25, 2024
Aligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MD
Apr 09, 2024
Aligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024
Apr 03, 2024
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Mar 27, 2024
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
Mar 18, 2024
Aligos Therapeutics Announces the Initiation of the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
Mar 12, 2024
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2023 Financial Results
Mar 05, 2024
Aligos Therapeutics to Announce 4th Quarter 2023 Financial Results on March 12, 2024
Displaying 1 - 10 of 13